Suppr超能文献

酵母TOP2中的一种突变与细菌中的喹诺酮耐药突变同源。与大肠杆菌gyrA的Ser83同源的氨基酸发生突变会改变对真核拓扑异构酶抑制剂的敏感性。

A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.

作者信息

Hsiung Y, Elsea S H, Osheroff N, Nitiss J L

机构信息

Developmental Therapeutics Section, Children's Hospital Los Angeles, California 90027, USA.

出版信息

J Biol Chem. 1995 Sep 1;270(35):20359-64. doi: 10.1074/jbc.270.35.20359.

Abstract

In prokaryotic type II topoisomerases (DNA gyrases), mutations that result in resistance to quinolones frequently occur at Ser83 or Ser84 of the gyrA subunit. Mutations to Trp, Ala, and Leu have been identified, all of which confer high levels of quinolone resistance. Extensive segments of DNA gyrase are homologous to eukaryotic topoisomerase II, and Ser741 of yeast TOP2 is homologous to Ser83 of prokaryotic DNA gyrA. Introduction of the Ser741-->Trp mutation into yeast TOP2 confers resistance to 6,8-difluoro-7-(4'-hydroxyphenyl)-1-cyclopropyl- 4-quinolone-3-carboxylic acid (CP-115,953), a fluoroquinolone with substantial activity against eukaryotic topoisomerase II, whereas changing Ser741 to either Leu or Ala does not change sensitivity to quinolones. Interestingly, Ser741-->Trp in the yeast TOP2 also confers hypersensitivity to etoposide. Sensitivity to intercalating anti-topoisomerase II agents such as amsacrine is not changed by any of the three mutations. The topoisomerase II protein carrying the Ser741-->Trp mutation was overexpressed and purified. The purified mutant enzyme had enhanced levels of etoposide stabilized covalent complex as compared with the wild type enzyme and reduced cleavage with CP-115,953. Unlike the wild type enzyme, etoposide-stabilized cleavage is not readily reversible by heat. We suggest that Ser741 is near a binding site for both quinolones and etoposide and that the Ser741-->Trp mutation leads to a more stable ternary complex between etoposide, DNA, and the mutant enzyme.

摘要

在原核生物II型拓扑异构酶(DNA促旋酶)中,导致对喹诺酮类药物耐药的突变经常发生在gyrA亚基的Ser83或Ser84位点。已鉴定出突变为色氨酸、丙氨酸和亮氨酸的情况,所有这些突变都赋予高水平的喹诺酮类药物耐药性。DNA促旋酶的大片段与真核生物拓扑异构酶II同源,酵母TOP2的Ser741与原核生物DNA gyrA的Ser83同源。将Ser741→Trp突变引入酵母TOP2可使其对6,8 - 二氟 - 7 -(4'-羟基苯基)- 1 - 环丙基 - 4 - 喹诺酮 - 3 - 羧酸(CP - 115,953)产生耐药性,CP - 115,953是一种对真核生物拓扑异构酶II具有显著活性的氟喹诺酮类药物,而将Ser741变为亮氨酸或丙氨酸不会改变对喹诺酮类药物的敏感性。有趣的是,酵母TOP2中的Ser741→Trp突变也赋予对依托泊苷的超敏感性。对诸如安吖啶等嵌入性抗拓扑异构酶II药物的敏感性不会因这三种突变中的任何一种而改变。携带Ser741→Trp突变的拓扑异构酶II蛋白被过度表达并纯化。与野生型酶相比,纯化的突变酶具有更高水平的依托泊苷稳定共价复合物,并且对CP - 115,953的切割减少。与野生型酶不同,依托泊苷稳定的切割不会因加热而轻易逆转。我们认为Ser741靠近喹诺酮类药物和依托泊苷的结合位点,并且Ser741→Trp突变导致依托泊苷、DNA和突变酶之间形成更稳定的三元复合物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验